Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C595
- Development stage
- Unknown
- Lead developer
- University of New South Wales
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intravesical
01
Overview
C595 is a murine monoclonal antibody (IgG3) that specifically targets the protein core of Mucin 1 (MUC1), recognizing the cancer-associated epitope (MUC1-CE) defined by the tetrameric motif RPAP. It is primarily utilized as a targeting moiety in radioimmunotherapy (RIT) and molecular imaging. When conjugated with radionuclides such as Actinium-225 ([225Ac]Ac-DOTA-C595) or Lutetium-177 ([177Lu]Lu-DOTA-C595) via the DOTA chelator, C595 facilitates the targeted delivery of cytotoxic alpha or beta radiation to MUC1-overexpressing tumor cells. This approach is being investigated for the treatment of aggressive malignancies, including pancreatic ductal adenocarcinoma (PDAC) and bladder cancer, where it aims to induce dense cellular damage and overcome therapeutic barriers such as hypoxia.
- Other names
- anti-MUC1 monoclonal antibody C595anti-MUC-1 monoclonal antibody C595anti-MUC 1 monoclonal antibody C595murine monoclonal antibody C595
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on C595.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C595.